Precision diagnostics Integrity Laboratories focuses on molecular diagnostics and precision medicine, offering potential partnerships with healthcare systems and payer networks seeking advanced, high-complexity clinical testing to improve patient outcomes and reduce costs.

Rapid innovation Recent milestones include launching a quantitative COVID-19 test and the Intercept PCR platform, highlighting a track record of fast-adoption capabilities and opportunities to collaborate on expanding pathogen panels and high-sensitivity assays.

Strategic leadership With a Chief Scientific Officer appointed and a recognized innovator award, the company demonstrates strong scientific leadership and credibility, making it a compelling partner for co-development, validation studies, and joint research initiatives.

Niche to scale Despite a small employee base, the company has revenue in the mid-range (10-25M) and aims to partner with large healthcare networks, suggesting opportunities to engage via channel partnerships, reference lab services, and contract testing for expanding clinical portfolios.

Expansion opportunities Leveraging its platform and diverse pathogen testing capabilities, Integrity Laboratories can explore expansion into high-complexity panels for specialty clinics, integrated diagnostics with electronic health records, and payer-driven value-based testing programs.